Teachers Advisors LLC increased its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 5.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 67,746 shares of the biotechnology company’s stock after purchasing an additional 3,681 shares during the quarter. Teachers Advisors LLC owned approximately 0.16% of Anavex Life Sciences Corp. worth $360,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of AVXL. Bank of New York Mellon Corp raised its holdings in shares of Anavex Life Sciences Corp. by 5.5% in the 1st quarter. Bank of New York Mellon Corp now owns 111,880 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 5,826 shares during the period. JPMorgan Chase & Co. bought a new stake in Anavex Life Sciences Corp. during the 1st quarter valued at $105,000. American International Group Inc. raised its holdings in Anavex Life Sciences Corp. by 7.1% during the 1st quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,329 shares during the period. Vanguard Group Inc. raised its holdings in Anavex Life Sciences Corp. by 13.1% during the 1st quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock valued at $8,528,000 after acquiring an additional 171,577 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Anavex Life Sciences Corp. by 16.8% during the 1st quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock valued at $1,589,000 after acquiring an additional 39,934 shares during the period. 24.47% of the stock is currently owned by institutional investors.

Shares of Anavex Life Sciences Corp. (AVXL) opened at $4.02 on Thursday. Anavex Life Sciences Corp. has a 1-year low of $3.11 and a 1-year high of $6.64.

A number of brokerages have issued reports on AVXL. Maxim Group reissued a “buy” rating and set a $15.00 target price on shares of Anavex Life Sciences Corp. in a report on Thursday, July 20th. Zacks Investment Research raised shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a report on Wednesday, September 6th. ValuEngine cut shares of Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. Finally, Noble Financial reissued a “buy” rating and set a $15.00 target price on shares of Anavex Life Sciences Corp. in a report on Friday, September 29th.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/16/teachers-advisors-llc-boosts-position-in-anavex-life-sciences-corp-avxl.html.

Anavex Life Sciences Corp. Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Institutional Ownership by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.